Pharma Journalist

Medical Devices and IVD conference 2021
2021-11-15 - 2021-11-16 | London, UK | Virtual Attendance Option Available
Navigating new legislations and strategies to comply with regulatory requirements
SMi is proud to announce the launch of their Medical Devices and IVD conference to be held in London in November 2021.
The MDR and IVDR updates will have a profound impact on the medical device industry, bringing certain products into regulatory scope that were previously excluded, introducing new manufacturing requirements, and increasing the burden for post-market surveillance. What does this mean for the future of the Medical Devices and IVD industry?
SMi’s inaugural Medical Devices and IVD conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these new regulations. In addition, the conference will examine MHRA Guidance on Post-Brexit IVD Regulations and consider the evolving regulatory landscape for digital health software. Join Europe’s leading Medical Device and IVD Conference which will address post-market surveillance and vigilance, clinical evaluations and investigations, medical device regulatory affairs in global markets, and much more.

BENEFITS OF ATTENDING:

Engage with notified body and competent authority representatives addressing key MDR and IVDR requirements
Gain insights from pharma regulatory experts in compliance and companion diagnostics
Understand the latest guidance on Post-Brexit IVD Regulations to overcome common challenges, in addition to considering evolving global regulations
Examine post-market expectations for surveillance and vigilance of your medical devices
Delve into how COVID-19 has impacted the MDR and IVD regulations

View the full agenda and speaker line-up online: www.medicaldevices-ivd.com/pjwl
Plus, post-conference workshop will be taking place on 17th November in London:
Implementing the EU MDR and Article 117, An Industry Perspective
Workshop Leader: Blake Green, Senior Manager Regulatory Affairs, Amgen
EARLY-BIRD RATES:

BOOK BY 30TH JUNE AND SAVE £200
BOOK BY 30TH SEPTEMBER AND SAVE £100

Registrations can be made on the event website at: www.medicaldevices-ivd.com/pjwl
CHAIR FOR 2021:
Andreas Stange, Vice President, TÜV SÜD
HEAR FROM EXPERT INDUSTRY SPEAKERS:

Jessica Wilkerson, Cyber Policy Advisor, FDA
Susan Neadle, Executive Director, Combination Products, Devices, Diagnostics & Digital Health Regulatory Affairs, Amgen
Claudia Dollins, Head, Precision Medicine & Companion Diagnostics, Bristol Myers Squibb
Michael Benecky, Senior Director, Global Regulatory Affairs, UCB Biosciences
Christophe Driesmans, Head of the Materiovigilance Entity, Federal Agency for Medicines and Health Products (FAMHP)
Melanie Donguy, Head Regulatory Affairs EMEA, Bayer Radiology
Marc Moal, Head of Product Delivery & Project Management, Merck Connected Health & Devices
Jim Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
Louise Place, Director, Devices, GlaxoSmithkline
Stefan Strasser, Head of Department, Austrian Medicines and Medical Devices Agency

5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
2021-11-16 - 2021-11-18 | Hilton Boston/Woburn, 2 Forbes Rd, Woburn, MA, 01801, United States
In the unprecedented array, and steady stream of novel, topical, and systemic agents entering various phases of drug development, for critical inflammatory and autoimmune dermatological conditions this year, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, returns to Boston for 2021. As the world’s leading, and only forum committed to overcoming significant R&D hurdles, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions, this forum is not to be missed.
With the rising demand for consolidation and precision medicine, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year, the 5th annual meeting addresses advances and challenges in genetic discoveries, antibody drug development, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.
Ensure you join this year’s 150+ expert community, in-person, to uncover recent studies evaluating critical inflammatory and auto-immune pathways, gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo.
Leave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline, evaluate optimal dose and dosing regimen to support formulation changes for your approach, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market.
To find out more visit: https://ter.li/e93ads

3rd Inflammasome Therapeutics Summit
2021-11-16 - 2021-11-18 | Virtual/Online
Discover the Intricacies of Inflammasome Regulation, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond
Built with Ventus Therapeutics, Inflammasome Therapeutics, Merck & more, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof of-concept clinical trials and beyond!
With a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021, this year’s summit will once again unite thought leaders in inflammasome drug development.
Expect to be involved in interactive discussions on:

How dysregulated inflammasome activation, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3
The interface of inflammasome signaling with innate immunity, microbial interactions, metabolism, neuroimmune and other systems
Leveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting
Identifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases, as well as infectious, ophthalmic, neurological and cancer settings

This year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases!
To Know more visit: https://ter.li/bdw0tf

3rd Exosome Based Therapeutic Development Summit
2021-11-16 - 2021-11-18 | Digital Event, EST
The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before, reuniting leading pharma, biotech, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, autoimmunity, COVID-19 and beyond.
Deep diving into the key challenges such as sourcing, characterization, cargo loading, manufacturing and clinical development, this year’s summit will be your comprehensive roadmap to realizing, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes.
Tailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points, join leading biopharmaceutical Directors, VPs and C-Level Executives to successfully optimize, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs
Key Highlights:

Shining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects, an exciting new approach for exosome therapeutics with Evelo Biosciences

Deep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19, oesteoarthirtus and gastrointestinal diseases with insights from Organicell, University of Athens & University of Louisville

Navigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion

Exploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio, Stem XO & Baker Heart and Diabetes Institute

Expanding the boundaries of engineering exosomes including cell selection, applications of the technology, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics, OmniSpriant & Exogenus Therapeutics

To know more visit: https://ter.li/h99vsb

Wnt & β-Catenin Targeted Drug Discovery Summit
2021-11-17 - 2021-11-18 | Digital Event
The Wnt & β-Catenin Targeted Drug Discovery Summit is the only meeting uniting leading pharma, pioneering biotechs and reputed academics under a mutual and ambitious objective of accelerating your novel Wnt/β-catenin candidates into clinic and market.
Built with Leap Therapeutics, Fog Pharma, Surrozen, Iterion Therapeutics, Genentech, and other leading companies, the summit will allow you to gain knowledge on the inhibition and activation of the Wnt pathway. You can be sure to take away practical insights and actionable strategies on how to harness this previously undruggable target.
With 24+ expert speakers, this is your definitive opportunity to be a part of this exciting and growing community, and this dedicated virtual summit will ensure you get your answers to your questions.
To find out more and view the 2021 speaker line-up, download the full event guide.

5 unmissable keynotes include:

Supercharging Your Wnt/β-catenin Clinical Program by Surrozen, Iterion Therapeutics, AntlarA & Leap Therapeutics
Getting a Grip on Wnt Biology to Theorize the Latest Opportunities & Understandings with Iterion Therapeutics, Genentech & Auburn University
Opportunities to Aid Drug Discovery & Further Research Efforts with Biovista & the DTRF
Delving into Immuno-Oncology to Further Oncological Treatment Efficacy, brought to you by UAB, Duke Cancer Institute & Shandong First Medical University
Harnessing Novel Pathways Approach to Drive Preclinical Insights delivered by
Fog Pharma, RedX Pharma & The University of Oxford

To know more about the Wnt & β-Catenin Targeted Drug Discovery Summit please click here.

Microbiome Connect: Gut Therapeutics USA
2021-11-17 - 2021-11-18 | 275 Tremont St, Boston, MA 02116, United States, MA, United States
Microbiome Connect: Gut Therapeutics USA, a two-day conference from the 17th – 18th of November 2021 and will bring you essential solutions to the challenges you face in the microbiome field. This industry-leading event will facilitate discussions concerning new clinical research, microbiome biomarkers, the latest regulatory developments, gut-organ axis, human clinical updates and much more. Hear from experts like Bernat Olle, CEO of Vedanta Bioscience, regarding the state of the market post-C Diff. therapy approval, and Diwakar Davar, to discuss his ground-breaking immuno-oncology research.

The event will have dedicated manufacturing steam; attendees will witness a showcase of solutions to scaling up your bacterial fermentation operation, highlighting the different culturing methodologies along with discussions regarding commercialization preparation. Joined by companies such as Takeda, Merck, and PRI, who will discuss the microbiome’s clinical future as a diagnostic and endpoint and examine how the industry can and should develop standardized biomarkers. Leading biotechs will discuss their latest clinical updates, mechanistic data, experimental methods, and clinical trial design.
Microbiome Connect will be hosting their annual skin and oral event at the same venue and dates, which all gut attendees will have access to. Download the agenda https://hubs.ly/H0RQsBQ0.

Microbiome Connect: Oral USA
2021-11-17 - 2021-11-18 | Join the Microbiome Connect community at the picturesque Courtyard by Marriott, Boston Downtown Boutique Hotel, 275 Tremont St, Boston, MA, 02116, United States
The Oral Microbiome is the second largest and diverse microbiota in the human body, harboring over 700 species of bacteria. A complex and constantly changing habitat, it is crucial in maintaining not only oral health and oral diseases, but systemic health conditions across the body. To date, over 50 systemic diseases have been linked to an unbalanced oral microbiome, and research in this space is accelerating. Further developing a collective understanding of the role of the oral microbiome in health and disease will allow further developments in drug development, oral health, and targeted therapies in the future.
Join us at the 6th Annual Microbiome Connect to discover the latest research relating to the oral microbiome, and its critical and underappreciated role in human health. Be a part of the discussion surrounding pre- and pro-biotics, innovative therapies.
Find out more >>> https://hubs.ly/H0T0d430

Microbiome Connect: Skin USA
2021-11-17 - 2021-11-18 | Boston, MA, USA
Love the skin you’re in? How about the bugs on it?
Over the six years we’ve run Microbiome Connect: Skin, the field has changed drastically. In a short period, the field has gone from fringe to mainstream, from quantifying the size of bacterial populations to understanding their function. As the field continues to commercialize, it is time to ask how this research can benefit consumers. How can the skin microbiome be leveraged as a source of biomarkers, as a therapeutic modality, as an understandable term to consumers?
Join us in Boston for a two-day face-to-face event, attended in the past by the likes of P&G, Jackson Laboratory, and the FDA. Unravel the function of the skin microbiome and apply the latest findings to your future products. See you in November!
To know more visit: https://hubs.ly/H0W7lQ90

CPhI & P-MEC China Virtual Expo Connect 2021
2021-11-18 - 2021-12-18 | Online
Virtual Expo Connect” is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. Powered by PharmaSources.com, Virtual Expo Connect builds an online platform to be accessed from anywhere, adding valued services and infinite opportunities to connect, learn, trade and grow.
To know more visit: https://bit.ly/3ASODPZ

Ophthalmic Drugs Conference 2021
2021-11-22 - 2021-11-23 | Holiday Inn, Kensington, London, UK, London, United Kingdom
Exploring the future of ocular drug development
SMi proudly presents the 4th Annual Ophthalmic Drugs Conference taking place on the 22nd-23rd of November 2021, in London.
The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

As Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.
This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy.
To register or for more information visit: www.ophthalmicdrugs.com/pjwl
BENEFITS OF ATTENDING:

INSIGHT into the newest techniques in ocular drug design and delivery
EXPLORE the impacts and applications of controlled release technologies
LEARN how advanced medical devices are changing the face of combined therapy
UNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs

WHO SHOULD ATTEND:

Ophthalmic Lead
Clinical Director
Senior Medical Advisor
Franchise Head
Business Manager
Senior Scientist
Senior Vice President
Medical Director
Therapeutic Area Head
General Manager
International Scientific Advisor

Early-Bird Rates

BOOK BY JUNE 30TH TO SAVE £300
BOOK BY SEPTEMBER 30TH TO SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #OphthalmicDrugs
LinkedIn: follow our company page – search ‘SMi Pharma’
Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk

5th Annual NASH Summit 2021
2021-11-29 - 2021-12-01 | Digital Event
Grounding the scientific data into actionable insights for drug sponsors, the 5th NASH Summit is the outstanding forum and unrivalled platform for biotech and pharma to regroup, reassess and realign their NASH pipeline strategy.

Uniting 100+ NASH experts from the EMA, Novartis, Gilead, Pfizer, Eli Lilly, Takeda, AstraZeneca, Merck, Janssen, Ionis, Novo Nordisk, the FDA and more, including stakeholders at the helm of NASH drug development and on the periphery, this industry focused forum is bringing together content perfectly aligned with wherever you sit on prioritising NASH, so you can continue to keep on top of this huge unmet medical need and massive opportunity for drug sponsors to scratch the pad of available, approved, NASH therapeutics.
To know more visit: https://nash-summit.com/

Cytokine-Based Cancer Immunotherapies Summit Boston
2021-11-30 - 2021-12-02 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The only in person dedicated industry forum supporting the development of robust cytokine-based cancer immunotherapy platforms (cytokine muteins, antibody-cytokine fusion proteins (immunokines), anticancer vaccines, and cancer-directed antibodies) to deliver targeted, durable therapeutic interventions to solid tumor and hematological cancer indications.
This comprehensive, drug development focused agenda will showcase the latest concepts and molecular engineering approaches being utilized by biopharma and research groups to help you overcome the challenges in:

Toxicity management – engineering selectivity, targeting and half life modulation
Optimizing the risk benefit by dose and schedule optimization
Achieving safe and acceptable delivery
Understanding the potentials for combination
Delving into the clinical data to understand the translational side

You will have the opportunity to join a pre-conference workshop day exploring pre-clinical models for cytokine research and the world of cytokines in inflammatory disease, providing insight into where the world of cytokine research is going beyond oncology.
Join this exclusive community of cytokine pioneers to network and learn from the leading experts in pharma, biotech and academia, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications.
Across 3 content packed days, 30+ experts will converge to discuss novel cytokines, the shortfalls of these therapies and how to learn from the pitfalls of the first cytokine era – this is not one to miss!
To know more visit: https://ter.li/gwz2x1

Rare & Genetic Kidney Disease Drug Development Summit
2021-11-30 - 2021-12-02 | Digital Event
Marrying unmissable insights from global renal experts, the 1st Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to provide you with transformative perspectives from identifying genetic drivers of rare kidney diseases to innovative trial design in small disease populations to accelerate progress of your genetic kidney disease pipeline.
Hear from industry heavyweights including Sanofi Genzyme, Alexion, AstraZeneca, Regulus Therapeutics, Chinook Therapeutics, Ionis Pharmaceuticals, Novartis, Otsuka Pharmaceutical Companies and many more to ignite your entry to the rare and genetic kidney disease landscape and confidently progress from proof of concept to the clinic.
Discover pivotal advances in disease modelling with stem cell-derived kidney organoids, explore opportunities for comprehensive genetic diagnosis and patient stratification, and join the conversation on progressing surrogate biomarkers and endpoints to guide strategic decisions on your pipeline in ADPKD, Alport Syndrome and more.
Get involved to understand why interest in rare and genetic kidney diseases is exploding and keep up to date with the latest opportunities for genetic intervention.
To know more visit: https://ter.li/k0fu1i

3rd Gene Therapy for Neurological Disorders
2021-12-06 - 2021-12-09 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Returning to Boston this December, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.
With 40+ expert leaders from the likes of Taysha Gene Therapies, Passage Bio, AskBio, Neurogene, Affinia Therapeutics and Alcyone Therapeutics sharing their progress, don’t miss the chance to join the industry’s definitive physical conference to make new connections and reconnect with your friends and colleagues.
Over 4 comprehensive days of networking, presentations and discussion sessions, this meeting will enable you to:

Discuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS
Evaluate current safety and toxicity strategies to navigate off target effects including redosing options
Evaluate intraparenchymal, intra-cisterna magna, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution
Hear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development
Review pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation
Learn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity
Optimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients
Discover the novel indications being targeted by gene therapies such as epilepsy, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines

View your copy of the event guide now: https://ter.li/yrofx9

iPSC-Derived Cell Therapies Summit
2021-12-07 - 2021-12-09 | Virtual/Online
Capitalize on the Scalable & Diverse Potential of iPSC-Derived Therapies By Defining Differentiation Protocols, Optimal Cell Line Selection & Optimizing Gene Engineering To Accelerate Successfully Into the Clinic
The explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy, with these cells establishing its place as the optimal starting material for cell therapies targeting cancer, autoimmune, cardiac disease and much more.
The iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy, including safety concerns with differentiation protocols, lack of regulatory guidance, and licensing issues.
Get caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences, Kite Pharma, HeartSeed, and Exacis, to understand the broad applicability of iPSCs, advances in novel gene engineering approaches, and translational lessons learned to advance your pipeline to clinical success.
Leave this meeting with the knowledge and connections to landscape the clinical progression, outline GMP compliant processes for scale up, and share strategies to ensure consistency in starting material.
This is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia and be at the forefront of the future of cell therapy by joining the mission to develop safe, scalable and cost-effective iPSC-derived therapies.
To Know more visit: https://ter.li/e7gdu7

Synthetic Biology-Based Therapeutics Summit
2021-12-07 - 2021-12-09 | Digital | EST
Engineer ‘Intelligent’, Controllable Drugs at the First Technical Meeting Dedicated to Advancing the Therapeutic Applications of Synthetic Biology
This year, the synthetic biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially.
The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.
With an agenda curated by leaders in synthetic biology-based therapies at Synlogic, Merck, Bayer, Senti Bio, MIT and GSK, the Synthetic Biology-Based Therapeutics Summit will provide strategic insights to deploy synthetic biology as a tool for discovery, through to therapeutic applications.
Explore innovations in circuit design and implementation, harnessing the power of computation and AI to better design functioning circuits and uncover novel components which elicit therapeutic benefit. Tackle manufacturing challenges to scale up synthetic biology-based therapeutics with gold-standard quality control and characterization.
To Know more visit: https://ter.li/19 mj8t

3rd Annual Targeted Radiopharmaceuticals (TRP) Summit
2021-12-07 - 2021-12-09 | Berlin Germany, & Online
The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data, there has been huge research investment, on both sides of the Atlantic, on how to deliver radiation therapy directly and specifically to tumours.
For the 2021 edition of this conference, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content.
You can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation.
As the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies, we strive to tackle topics that are on every drug developer’s mind:

How do we identify and validate new targets?
Can we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?
How do we improve current clinical design methodologies and patient selection strategies?
Where can improvements be made to the current supply and fulfilment models?

To know more visit: https://ter.li/r1oll2

4th Commercializing Clinically Validated Digital Therapeutics Summit
2021-12-07 - 2021-12-09 | Virtual Event
The 4th Commercializing Clinically Validated Digital Therapeutics Summit returns in December of 2021 as the only industry-led meeting deep-diving on stakeholder alliance and partnership to accelerate DTx scalability, to enable building sustainable & viable business models.
DTx is happening, and happening fast on a global scale. The amount of investment continues to surge, and is expected to reach $15,176m in 2027. Following the pandemic, with more emphasis on digital medicine, telemedicine, and decentralized clinical trials, DTx adoption has peaked. Now is the time to join with key stakeholders across regulatory, pricing, physician engagement, real world evidence, commercial functions, patient adherence and adoption to combat the challenges and ensure delivery of cutting edge DTx to your patients.

Furthermore, the pandemic has been the major catalyst to DTx adoption with tremendous benefits brought to patients, physicians for treatment, and remote clinical trials that made 2021 an inflection point for the DTx industry.
Across 3 days covering extensive and valuable content, we will bring together expert speakers to share their data on case studies of lessons learnt and keys to success, as well as insights into venturing into effective partnerships. This will give you the tools to conquer your most crucial challenges and accelerate sustainable scalability and adoption of your digital therapeutic.
Whether you are a drug, med device or a DTx developer, this is your must-attend event in 2021. Hear from your peers’ journeys and lessons learned, and re-engage in the long awaited dialogue to generate clinical and RWE, in order to serve our patients in need beyond just a pill!
To know more visit: https://ter.li/cyw0ze

4th RNA-Targeted Drug Discovery Summit
2021-12-07 - 2021-12-09 | Digital Event, EST
The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.
Join the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field.
We’re back in 2021 with a more comprehensive program than ever before & we’d love you to join us!
Key Highlights:

Expand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum, Arrakis, PTC Bio& Expansion Therapeutics

Optimize and advance your RNA structural insights to guide the successful discovery & development of your RNA targeted small molecule with insights from Novartis, AstraZeneca, Stanford University &National Cancer Institute

Evaluate tested & novel structure-based methods for understanding RNA-ligand interactions and binding sites alongside academic leaders Hashim Al-Hashimi, Matthew Disney,Amanda Garner, Aaron Frank & Anthony Mustoe

Overcome selectivity, specificity & toxicity challenges and accelerate the translation of your RNA small molecule pipeline into clinical development with discussions from
Anima Biotech, MD Anderson Cancer Center & AstraZeneca

Discovery of novel chemical matter & new chemical space for small molecule intervention with insights from Roche, University of Michigan, Baylor College Medicine, Remix Therapeutics, Ladder Therapeutics &Biosplice Therapeutics

To know more visit: https://bit.ly/3mWyANC

Microbiome Connect: Gut Therapeutics Europe
2021-12-07 - 2021-12-08 | Amsterdam, Venue TBC
Join us in Amsterdam from 7th – 8th December 2021 to find out more about why biotherapeutic products are progressing through clinics worldwide. As this trending topic gains more exposure and fast approaches commercialisation various challenges have presented themselves. Issues in areas such as key regulatory, manufacturing and supply chain are amongst some of the themes emerging.
Companies such as Stellate Therapeutics, TargEDys, EVERIMMUNE, Nestlé are amongst those committed to the event, and you can reach out to them directly by securing your place.
Download the agenda here to view the speaker faculty and partners for 2021: https://hubs.ly/H0X0Lk_0

TIGIT Therapies Summit
2021-12-07 - 2021-12-09 | Digital
TIGIT therapies have seen promising clinical validation, spearheading the next wave of Immune Checkpoint Inhibitors. As such there has been an explosion of interest and high-scale investment into this exciting space.
Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused at propelling this next generation inhibitor to clinical use.
Ensure your TIGIT program reaches full clinical potential through hearing from experts about optimizing the mechanism of action, refining Fc receptor co-engagement, devising effective drug design, rationalizing checkpoint combinations and utilizing biomarkers to harness the therapeutic potential of the TIGIT and DNAM-1/CD226 axes.
Join leaders in TIGIT development from GSK, Gilead Sciences, Arcus, iTeos, Compugen, BeiGene, Seattle Genetics, Mereo BioPharma, Harvard, Stanford and more!
This event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use. Download the event guide to see how you can get involved.

INDIAN PHARMA EXPO & BUSINESS EXCELLENCE AWARDS 2021
2021-12-10 - 2021-12-11 | Hall 12 A, Pragati Maidan, New Delhi, New Delhi, 110001, India
Indian Pharma Expo (IPE) will provide an opportunity for the participating companies to display their products & services to the gamut of visitors, globally from pharma and healthcare industries. The 2-day expo will bring together eminent personalities from various sectors of pharma, non-pharma and healthcare industries. IPE is one stop juncture to all those who are planning to expand their business through various channels of franchise and distribution; as well as wholesalers and hospital purchase personnels who seek to buy bulk products on concessional rates.
The Indian Pharma Expo will also showcase the latest trend and technologies in the pharmaceuticals, drugs and formulations. The Expo is expected to witness approx. 10,000 visitor’s footfall displays of latest pharmaceutical machinery, packaging equipments, software technology for pharma industry and management and more. Direct access to highly targeted senior pharma executives, buyers, procurement managers, contract manufacturers and hospital administration. Multiple meetings will be held with managers and business development managers who are looking for new supplies, building strategic partnerships or entering into new ventures. The Expo will feature international-cum-pharma machinery pavilion. The Expo aimed at bringing together all the pharma professionals under one roof, the pharmaceutical exhibition focused on knowledge, technology and business development.

SMi's Pre-Filled Syringes and Injectable Drug Devices
2022-01-12 - 2022-01-13 | Virtual Conference: Online Access Only
SMi’s Pre-Filled Syringes and Injectable Drug Devices
12th January to 13th January 2022,
Virtual Conference: Online Access Only
Conference: 12 – 13 January 2022
Focus Day: 11 January 2022
Location: Virtual Conference: Online Access Only
Website: http://pre-filled-syringes.com/pharmajournalist/WL
Sponsored by: BD Medical – Pharmaceutical Systems, Crux, Nemera, Zeon Europe GmbH
Chaired by:
Bjørg Kaae Hunter, Department Manager, RA CMC & Device; RA NextGen Drug-Device, Novo Nordisk and Daniel Latham, Head Connected Health Product Development, Novartis
The Future of Drug Delivery and Combination Product Device Design
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is adapting to the delayed EU MDR, takeaways from the global pandemic and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation. Part of the leading injectables series of events, SMi’s 14th annual conference will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry.
#PFSSMi
Key Reasons to Attend:

Engage with industry leaders on the key takeaways from the pandemic and how this can be applied to future accelerated development
Explore updates to drug device combination product design approaches putting the user first with industry case studies from big pharma
Assess the current landscape of device delivery mechanisms and how industry can work together to promote innovation
Understand the landscape of delivery for novel drug products, fragile molecules and long acting injectables in the interactive panel discussion

Download the brochure at: http://pre-filled-syringes.com/pharmajournalist/WL
Who Should Attend?
Drug-delivery developers, Medical Device Engineers, Primary Packaging material designers, Secondary packagers, Smart device developers, Training device developers, Device-safety solution providers, Drug developers

SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
2022-01-17 - 2022-01-18 | London, UK
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
Conference: 17 – 18 January 2022
Workshops: 19 January 2022
Location: Virtual Conference: Online Access Only
Website: http://www.pharma-microbiology.com/PJwl
Sponsored by: CTL-MAT, Ecolab and Microgenetics
Chaired by: Di Morris, Clinical Auditor, AstraZeneca
Exploring Robust Risk-Based Microbiological Control Strategy
SMi’s flagship microbiology conference is celebrating its 10 year anniversary. The conference taking place on 17 and 18 January 2021 in London, UK will bring together microbiology industry experts.
Microbiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. The two-day conference will explore the most pressing topics in this thriving field, from the movement toward process automation and minimisation of operator intervention, to the latest technologies in rapid microbiological testing methods and data integrity.
#SMiPharmaMicroUK
Key Reasons to Attend:

Discover case studies in establishing holistic Contamination Control Strategies and Real-Time Viable Air Particle Counting with leaders in the pharmaceutical industry
Gain insight the current state of Endotoxin testing, including alternative test methods and strategic approaches to method validation
Explore the best practice in data integrity and the automation of environmental monitoring in the Microbiology Quality Control Lab
Join the important panel discussion on diversity and inclusion in the workplace with an experienced line-up of speakers
Discuss the latest developments in the detailed, rapid detection of microbes in pharmaceutical water

Download the brochure at: http://www.pharma-microbiology.com/PJwl
Who Should Attend?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist

3rd Glioblastoma Drug Development Summit
2022-01-18 - 2022-01-20 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma.
Through investigating the clinical implementation of diverse mechanisms of action, including, DNA damage repair, immunotherapy, oncolytic viruses, cholesterol metabolism, PARP inhibitors and more, we strive to address the urgent need for novel and much improved treatments for this devastating disease.
Tackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials.
With a huge unmet medical need for effective treatments and too many clinical failures to overcome, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives.
Join us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients.
To know more visit: https://ter.li/2bmg9q

SMi’s Transdermal and Microneedle Delivery
2022-01-24 - 2022-01-25 | Virtual Conference: Online Access Only
SMi’sTransdermal and Microneedle Delivery
24-25 January 2022
Workshop: 26th January 2022
Virtual Conference: Online Access Only
www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL
#SMiTransdermal
Sponsored by: LTS Lohmann Therapie-Systeme AG and QuadMedicine
Co-Chaired by:
Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie Ltd
SMi’s inaugural conference: Transdermal and Microneedle delivery will take place on 24th – 25th January 2022
SMi is proud to present the Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, Virtual Conference: Online Access Only. Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.
The conference will consider key developments in the transdermal drug delivery field, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery, advances in microarray patches, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.
This two-day agenda offers you peer-to-peer networking with leaders in transdermal and microneedle delivery. We look forward to welcoming you to the conference in January.
Key Reasons to Attend:

Gain insight into developments in microneedles for drug delivery and diagnostics
Hear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance
Explore new applications of microneedle technology in vaccinations
Discover advances in design and application of transdermal patches
Explore and benchmark against industry developments through case studies and real world examples in device development for microneedles

Download the brochure at: www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL
Who Should Attend?

Drug-Delivery Device Developers
Microneedle Device Developers
Transdermal Delivery Developers
Microarray Patch Developers
Medical Device Engineers
Primary Packaging Material DesignersSecondary Packagers
Smart Device Developers
Training Device Developers
Device-Safety Solution Providers
Drug Developers
Transdermal Drug Product Developers

6th Microbiome Movement - Drug Development Summit Europe
2022-01-25 - 2022-01-27 | The Tower Hotel, St. Katharine's Way, London, E1W 1LD, United Kingdom
Decipher Mechanisms of Action, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research

Whilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics, there remain analytical challenges and translational bottlenecks that the community must come together to overcome, to redefine biopharmaceutical treatment and diagnostic options.
The community is now closer than ever to obtaining an available, approved and commercial microbiome-based therapeutic. This conference joins scientists, clinicians, entrepreneurs and academics, to help assist this success. Persistent hurdles and ongoing challenges with microbiome drug development mean that real-life discussions and learnings are imperative to moving this exciting field forward.
From understanding the microbiome functionality, leveraging lessons from pre-clinical and clinical development, scaling manufacturing processes and regulation hurdles, our discussion will leave you with a holistic view of the European end-to-end development of microbiome therapeutics.
The Microbiome Movement provides the perfect opportunity to actualise the therapeutic promise that the microbiome has provided, by bringing these challenges to the forefront and tackling them head on over three days of extensive content. With the sharing overall aim to commercialise a microbiome-based product.
To know more visit: https://ter.li/rk0suq

HFpEF Drug Discovery & Development Summit 2022
2022-01-25 - 2022-01-27 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes.
The HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures.
With 20+ hours of content, an interactive workshop, and over 5 hours of networking with key industry leaders from Amgen, Cardiobiopharma, AstraZeneca, NeoProgen, Eli Lilly, Bayer, Novartis, and more, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field.
Make this your 2022 must-attend meeting and network with 80+ senior CSOs, CEOs, research scientists, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide.
Take a look at the full event guide here.

TGF-β for Immuno-Oncology Drug Development Summit
2022-01-25 - 2022-01-27 | Virtual Event
It is clear the world of TGF-β contains vast potential and excitement, in the past year alone we have seen great advances, clinical setbacks, and novel insights into the role of TGF-β.
Over the last 12 months, we have seen so many highs and lows, including clinical updates from large pharma such as Novartis, Oncotelic Therapeutics, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate.
With the vast volume of candidates moving into the clinic, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression.
Tailored with 31+ senior leaders, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from biology to translational modeling, from biomarkers to clinical trial design across 3 days.
What’s New?

31+ world-class speakers from Scholar Rock, Novartis, Pfizer, Mestag Therapeutics, Takeda, Cue Bio, Genentech, and more
2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned
A TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target

To know more visit: https://ter.li/nep8yi

DDR, ATR & PARP Inhibitors Summit
2022-01-25 - 2022-01-27 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.
This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications.
If you are a research team striving to create best-in-class DDR therapeutics, this is the specific networking forum that has been curated with you in mind.
What Will We Cover?

Delve into the progress in PARP, ATR & Wee1 including biomarker understanding with AstraZeneca, Bayer, Repare, Merck KGaA, Atrin Pharma, IMPACT Therapeutics, Onxeo, FoRx & Zentalis

Optimize pre-clinical development through models, novel methodologies & imaging technologies to revolutionize translation with NCI, XPose Therapeutics, Dana-Farber Cancer Institute & Harvard

Uncover the therapeutic potential & progress in targeting Polθ, WRN, CHK1, DNA-PK, USP1, PARG, PKMYT1 with Artios Pharma, Harvard, NERx Bio, KSQ Therapeutics, IDEAYA & Repare Therapeutics

Discover the clinical updates on combination, dosing, scheduling & future directions for this exploding field with Newcastle University, MD Anderson, National Brain Tumor Society, Yale, Breakpoint Therapeutics & Harvard

Network In Person with your peers, ask your burning questions, build connections, and fully immerse yourself in the world of DDR therapeutics.

A Virtual Attendance Option, giving you access to the same premium quality content as the in-person event, dedicated virtual networking opportunities, & the ability to engage with our event partners

To know more visit: https://ter.li/uzjvgi
